| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mahmoud M Iravani, Michael J Jackson, Mikko Kuoppamäki, Lance A Smith, Peter Jenne. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 23. issue 27. 2003-11-04. PMID:14534244. |
mdma similarly alleviated dyskinesia induced by the selective dopamine d2/3 agonist pramipexole. |
2003-11-04 |
2023-08-12 |
Not clear |
| O Rascol, J J Ferreira, P Payoux, Ch Brefel-Courbon, J L Montastru. [Management of levodopa-induced dyskinesia]. Revue neurologique. vol 158 Spec no 1. 2003-10-30. PMID:12690671. |
to prevent, at least partly, priming for dyskinesias is attempted by the early use of dopamine d2 agonists, which delays the need for levodopa. |
2003-10-30 |
2023-08-12 |
Not clear |
| Michel Cyr, Jean-Martin Beaulieu, Aki Laakso, Tatyana D Sotnikova, Wei-Dong Yao, Laura M Bohn, Raul R Gainetdinov, Marc G Caro. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proceedings of the National Academy of Sciences of the United States of America. vol 100. issue 19. 2003-10-29. PMID:12958210. |
here we document that mice with persistently elevated extracellular dopamine, resulting from inactivation of the dopamine transporter gene, sporadically develop severe symptoms of dyskinesia concomitant with apoptotic death of striatal dopamine-responsive gamma-aminobutyric acidergic neurons. |
2003-10-29 |
2023-08-12 |
mouse |
| E C Hirsch, G Höglinger, E Rousselet, T Breidert, K Parain, J Feger, M Ruberg, A Prigent, C Cohen-Salmon, J M Launa. Animal models of Parkinson's disease in rodents induced by toxins: an update. Journal of neural transmission. Supplementum. issue 65. 2003-10-20. PMID:12946051. |
these symptoms should be alleviated by dopamine replacement therapy, which may in turn lead to side effects such as dyskinesia. |
2003-10-20 |
2023-08-12 |
Not clear |
| Peter Jenne. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology. vol 58. issue 4 Suppl 1. 2003-09-15. PMID:11909980. |
long-acting dopamine agonists produce a lower incidence of dyskinesia than levodopa (l-dopa) when they are used as monotherapy in either pd or in drug-naïve 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp)-treated primates. |
2003-09-15 |
2023-08-12 |
Not clear |
| Peter Jenne. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology. vol 58. issue 4 Suppl 1. 2003-09-15. PMID:11909980. |
however, once priming has occurred, dopamine agonists produce dyskinesia identical to that of l-dopa. |
2003-09-15 |
2023-08-12 |
Not clear |
| Peter Jenne. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology. vol 58. issue 4 Suppl 1. 2003-09-15. PMID:11909980. |
continuous administration of long-acting dopamine agonists may reverse the priming process initiated by l-dopa, markedly decreasing dyskinesia intensity with a minimal loss of antiparkinsonian activity, at least in mptp-treated primates. |
2003-09-15 |
2023-08-12 |
Not clear |
| Erwan Bézard, Sandrine Ferry, Ulrich Mach, Holger Stark, Ludovic Leriche, Thomas Boraud, Christian Gross, Pierre Sokolof. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature medicine. vol 9. issue 6. 2003-08-14. PMID:12740572. |
attenuation of levodopa-induced dyskinesia by normalizing dopamine d3 receptor function. |
2003-08-14 |
2023-08-12 |
monkey |
| Barbara Picconi, Diego Centonze, Kerstin Håkansson, Giorgio Bernardi, Paul Greengard, Gilberto Fisone, M Angela Cenci, Paolo Calabres. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature neuroscience. vol 6. issue 5. 2003-07-01. PMID:12665799. |
long-term treatment with the dopamine precursor levodopa (l-dopa) induces dyskinesia in parkinson's disease (pd) patients. |
2003-07-01 |
2023-08-12 |
rat |
| J M van Kampen, A Jon Stoess. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience. vol 116. issue 1. 2003-06-24. PMID:12535962. |
further investigation of dopamine d(3) receptor involvement in levodopa-induced dyskinesias is hampered by the lack of appropriately selective ligands for this receptor. |
2003-06-24 |
2023-08-12 |
rat |
| C E Clark. Dopamine agonist monotherapy in early Parkinson's disease. Hospital medicine (London, England : 1998). vol 64. issue 1. 2003-06-16. PMID:12572327. |
monotherapy with dopamine agonists may present an alternative approach with a reduced likelihood of developing dyskinesias. |
2003-06-16 |
2023-08-12 |
Not clear |
| Larry C Wienkers, Michael A Wynald. Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. vol 30. issue 12. 2003-05-13. PMID:12433806. |
(s,s)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride [(-)-osu6162] is a weak dopamine d2 receptor modulator that possesses potential for the treatment of levodopa (l-dopa)-induced dyskinesias in patients with parkinson's disease. |
2003-05-13 |
2023-08-12 |
human |
| Peter Jenne. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism & related disorders. vol 9. issue 3. 2003-04-29. PMID:12573867. |
there is now accumulating evidence that the pulsatile manner in which short-acting agents stimulate striatal dopamine receptors is a key contributing factor to the priming of the basal ganglia for dyskinesia induction. |
2003-04-29 |
2023-08-12 |
Not clear |
| Peter Jenne. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism & related disorders. vol 9. issue 3. 2003-04-29. PMID:12573867. |
it has been suggested that providing more continuous stimulation of dopamine receptors will avoid the development of motor complications, particularly dyskinesia. |
2003-04-29 |
2023-08-12 |
Not clear |
| Peter Jenne. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism & related disorders. vol 9. issue 3. 2003-04-29. PMID:12573867. |
these primate studies have demonstrated that long-acting dopamine agonists and levodopa given in combination with a catechol-o-methyl transferase (comt) inhibitor (to increase its relatively short half-life), induce significantly less dyskinesia than occurs with standard levodopa therapy. |
2003-04-29 |
2023-08-12 |
Not clear |
| H King, P Corry, T Wauchob, P Barcla. Probable dystonic reaction after a single dose of cyclizine in a patient with a history of encephalitis. Anaesthesia. vol 58. issue 3. 2003-04-08. PMID:12603456. |
her symptoms were suggestive of a lingual-facial-buccal dyskinesia as seen with dopamine antagonists. |
2003-04-08 |
2023-08-12 |
Not clear |
| Alice J Manson, Kirsten Turner, Andrew J Lee. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Movement disorders : official journal of the Movement Disorder Society. vol 17. issue 6. 2003-03-24. PMID:12465062. |
these results confirm that subcutaneous apomorphine monotherapy can reset peak-dose dyskinesia threshold in levodopa-treated patients and further reduce off-period disability after all available forms of oral medication, including long-acting dopamine agonists, have been tried. |
2003-03-24 |
2023-08-12 |
Not clear |
| Matthew J Hansard, Lance A Smith, Michael J Jackson, Sharon C Cheetham, Peter Jenne. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. European journal of pharmacology. vol 451. issue 2. 2003-03-14. PMID:12231385. |
dopamine reuptake inhibition and failure to evoke dyskinesia in mptp-treated primates. |
2003-03-14 |
2023-08-12 |
Not clear |
| Matthew J Hansard, Lance A Smith, Michael J Jackson, Sharon C Cheetham, Peter Jenne. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. European journal of pharmacology. vol 451. issue 2. 2003-03-14. PMID:12231385. |
in contrast, the selective dopamine reuptake inhibitor 1-(2-(bis-(4-fluorophenyl)-methoxy)ethyl)-4-(3-phenylpropyl) piperazine dihydrochloride (gbr 12909) reversed motor deficits in a dose-dependent manner but, unlike l-dopa, did not evoke established dyskinesia in these animals. |
2003-03-14 |
2023-08-12 |
Not clear |
| Matthew J Hansard, Lance A Smith, Michael J Jackson, Sharon C Cheetham, Peter Jenne. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. European journal of pharmacology. vol 451. issue 2. 2003-03-14. PMID:12231385. |
therefore, inhibition of dopamine reuptake does not evoke established dyskinesia in mptp-treated primates. |
2003-03-14 |
2023-08-12 |
Not clear |